Takuya Osada

USPTO Granted Patents = 11 (Patent Applications = 8)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 13(Granted Patents)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12083172 - Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the same (2024-09-10),

2. 11992697 - X-ray psoralen activated cancer therapy (X-PACT) (2024-05-28),

3. 11305131 - X-ray psoralen activated cancer therapy (X-PACT) (2022-04-19),

4. 11253580 - Cancer vaccines and methods of delivery (2022-02-22),

5. 11235043 - Vaccines against antigens involved in therapy resistance and methods of using same (2022-02-01),

6. 11207409 - X-RAY psoralen activated cancer therapy (X-PACT) with associated treatments (2021-12-28),

7. 10842857 - Vaccines against an oncogenic isoform of HER2 (ErbB2) and methods of using the same (2020-11-24),

8. 10842855 - Vaccines against an oncogenic isoform of ESR1 and methods of using the same (2020-11-24),

9. 10487143 - Vaccines against HER3 antigens and methods of using the same (2019-11-26),

10. 10441810 - X-ray psoralen activated cancer therapy (X-PACT) (2019-10-15),

11. 9956276 - Vaccines against antigens involved in therapy resistance and methods of using same (2018-05-01),

Title: Takuya Osada: Innovator in Cancer Therapeutics

Introduction

Takuya Osada is a prominent inventor based in Durham, NC, known for his significant contributions to cancer therapeutics. With a total of 11 patents to his name, he has made remarkable strides in the field of medical innovation, particularly in developing vaccines and treatment methods for cancer.

Latest Patents

Among his latest patents is a groundbreaking vaccine designed to combat an oncogenic isoform of HER2 (ErbB2). This innovative approach includes methods for reducing the likelihood of cancer or precancer developing resistance to therapeutic agents. The vaccine comprises a polynucleotide encoding a polypeptide correlated with the development of resistance to cancer treatments. Additionally, Osada's work includes methods for administering this vaccine alongside cancer therapeutics or checkpoint inhibitor immunomodulatory agents. Another notable patent is the X-ray psoralen activated cancer therapy (X-PACT), which involves injecting phosphors capable of emitting ultraviolet or visible light into diseased sites in the human or animal body.

Career Highlights

Takuya Osada has had a distinguished career, working with esteemed institutions such as Duke University and Immunolight, LLC. His innovative research has positioned him as a key figure in the development of advanced cancer treatment methodologies.

Collaborations

Throughout his career, Osada has collaborated with notable professionals, including Herbert K. Lyerly and Zachary C. Hartman. These partnerships have further enhanced his research and contributions to the field of cancer therapeutics.

Conclusion

Takuya Osada's work exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. His patents and research continue to pave the way for new therapeutic strategies that could significantly impact patient care.

This text is generated by artificial intelligence and may not be accurate.